{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:08:16Z","timestamp":1786993696449,"version":"build-2736575974"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005026","name":"Foundation Against Cancer","doi-asserted-by":"publisher","award":["2020\\u2013124"],"award-info":[{"award-number":["2020\\u2013124"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.lungcan.2025.108893","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T15:47:31Z","timestamp":1767455251000},"page":"108893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Multi-omic screening for pleural mesothelioma in Asbestos-Exposed Populations: A literature review and Recommendations"],"prefix":"10.1016","volume":"212","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6197-3987","authenticated-orcid":false,"given":"Kathleen","family":"Zwijsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Heirwegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Schillebeeckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elly","family":"Marcq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0527-1136","authenticated-orcid":false,"given":"Adrian","family":"Covaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken Op","family":"de Beeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7872-8622","authenticated-orcid":false,"given":"Jan P.","family":"van Meerbeeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8029-4093","authenticated-orcid":false,"given":"Jo","family":"Raskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2101-2783","authenticated-orcid":false,"given":"Annemiek","family":"Snoeckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9500-7461","authenticated-orcid":false,"given":"Kevin","family":"Lamote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lungcan.2025.108893_b0005","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00953-2019","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"55","author":"Scherpereel","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108893_b0010","first-page":"E254","article-title":"Guidelines for the diagnosis and treatment of malignant pleural mesothelioma","volume":"5","author":"van Zandwijk","year":"2013","journal-title":"J. Thorac. Dis."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108893_b0015","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","article-title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial","volume":"12","author":"Lim","year":"2024","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108893_b0020","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.00283","article-title":"Microsatellite Instability is Associated with the Presence of Lynch Syndrome Pan-Cancer","volume":"37","author":"Latham","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.lungcan.2025.108893_b0025","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMra1912719","article-title":"Perspectives on the Treatment of Malignant Pleural Mesothelioma","volume":"385","author":"Janes","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108893_b0030","first-page":"281","article-title":"Principles and practice of mass screening for disease","volume":"65","author":"Wilson","year":"1968","journal-title":"Bol. Oficina Sanit. Panam."},{"issue":"135","key":"10.1016\/j.lungcan.2025.108893_b0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1183\/09059180.00007014","article-title":"Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic","volume":"24","author":"R\u00f8e","year":"2015","journal-title":"Eur. Respir. Rev."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108893_b0040","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.semtcvs.2009.06.007","article-title":"Current status of screening for malignant pleural mesothelioma","volume":"21","author":"Pass","year":"2009","journal-title":"Semin. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2025.108893_b0045","unstructured":"International Agency for Research on Cancer, WHO Classification of Tumours, Thoracic Tumours (5th edn). 2020."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108893_b0050","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41588-023-01321-1","article-title":"Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity","volume":"55","author":"Mangiante","year":"2023","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108893_b0055","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.5858\/arpa.2023-0304-RA","article-title":"Guidelines for Pathologic Diagnosis of Mesothelioma: 2023 Update of the Consensus Statement from the International Mesothelioma Interest Group","volume":"148","author":"Husain","year":"2024","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"162","key":"10.1016\/j.lungcan.2025.108893_b0060","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0057-2021","article-title":"Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis","volume":"30","author":"Schillebeeckx","year":"2021","journal-title":"Eur. Respir. Rev."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108893_b0065","first-page":"402","article-title":"Mesothelioma: Scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108893_b0070","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1164\/rccm.201409-1687LE","article-title":"Ultra-low-dose chest computer tomography screening of an asbestos-exposed population in Western Australia","volume":"191","author":"Brims","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lungcan.2025.108893_b0075","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejrad.2018.02.017","article-title":"Low-dose chest computed tomography screening of subjects exposed to asbestos","volume":"101","author":"Kato","year":"2018","journal-title":"Eur. J. Radiol."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108893_b0080","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1634\/theoncologist.12-10-1215","article-title":"Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial\u2013an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002)","volume":"12","author":"Fasola","year":"2007","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108893_b0085","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/JTO.0b013e31819f2e0e","article-title":"Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure","volume":"4","author":"Roberts","year":"2009","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2025.108893_b0090","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108893_b0095","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13550-020-00669-3","article-title":"FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients","volume":"10","author":"Pavic","year":"2020","journal-title":"EJNMMI Res."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108893_b0100","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.acra.2017.03.006","article-title":"Can CT and MR Shape and Textural Features Differentiate Benign Versus Malignant Pleural Lesions?","volume":"24","author":"Pena","year":"2017","journal-title":"Acad. Radiol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108893_b0140","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1158\/1055-9965.EPI-07-0607","article-title":"Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study","volume":"17","author":"Amati","year":"2008","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108893_b0145","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1383-5718(00)00054-1","article-title":"Association between 8-hydroxy-2'-deoxyguanosine levels in DNA of workers highly exposed to asbestos and their clinical data, occupational and non-occupational confounding factors, and cancer","volume":"468","author":"Marczynski","year":"2000","journal-title":"Mutat. Res."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108893_b0175","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.lungcan.2013.09.017","article-title":"The degree of microRNA-34b\/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma","volume":"82","author":"Muraoka","year":"2013","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108893_b0180","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jtho.2018.10.163","article-title":"Peripheral Blood DNA Methylation as potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects","volume":"14","author":"Guarrera","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108893_b0185","doi-asserted-by":"crossref","unstructured":"Cugliari, G., et al., New DNA Methylation Signals for Malignant Pleural Mesothelioma Risk Assessment. Cancers (Basel), 2021. 13(11).","DOI":"10.3390\/cancers13112636"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108893_b0200","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ijc.34339","article-title":"Blood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: the EPIC prospective cohort","volume":"152","author":"Allione","year":"2023","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2025.108893_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.envpol.2024.124928","article-title":"Integrated DNA methylation analysis of peripheral blood from asbestos exposed populations and patients with malignant mesothelioma reveals novel methylation driver genes of diagnostic and prognostic relevance","volume":"362","author":"Feng","year":"2024","journal-title":"Environ. Pollut."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108893_b0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018232","article-title":"Association of MiR-126 with Soluble Mesothelin-Related Peptides, a Marker for Malignant Mesothelioma","volume":"6","author":"Santarelli","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108893_b0235","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.lungcan.2015.09.021","article-title":"Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma","volume":"90","author":"Santarelli","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108893_b0240","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9280170","article-title":"Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma","volume":"2017","author":"Weber","year":"2017","journal-title":"Dis. Markers"},{"key":"10.1016\/j.lungcan.2025.108893_b0225","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9645940","article-title":"MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: a pilot Study","volume":"2017","author":"Mozzoni","year":"2017","journal-title":"Dis. Markers"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108893_b0250","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/1055-9965.EPI-18-0453","article-title":"Four-miRNA Signature to Identify Asbestos-Related Lung Malignancies","volume":"28","author":"Santarelli","year":"2019","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108893_b0245","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13104-019-4113-7","article-title":"Are circulating microRNAs suitable for the early detection of malignant mesothelioma? results from a nested case-control study","volume":"12","author":"Weber","year":"2019","journal-title":"BMC. Res. Notes"},{"issue":"12","key":"10.1016\/j.lungcan.2025.108893_b0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114483","article-title":"Combination of MiR-103a-3p and Mesothelin Improves the Biomarker Performance of Malignant Mesothelioma Diagnosis","volume":"9","author":"Weber","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108893_b0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176680","article-title":"Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease","volume":"12","author":"Cavalleri","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.lungcan.2025.108893_b0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0275936","article-title":"Assessment of miR-103a-3p in leukocytes-No diagnostic benefit in combination with the blood-based biomarkers mesothelin and calretinin for malignant pleural mesothelioma diagnosis","volume":"17","author":"Jimenez-Ramirez","year":"2022","journal-title":"PLoS One"},{"issue":"50","key":"10.1016\/j.lungcan.2025.108893_b0285","doi-asserted-by":"crossref","first-page":"82700","DOI":"10.18632\/oncotarget.12408","article-title":"Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers","volume":"7","author":"Bononi","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108893_b0275","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2217\/bmm-2017-0224","article-title":"Clinical evaluation of circulating miR-548a-3p and-20a expression in malignant pleural mesothelioma patients","volume":"12","author":"Matboli","year":"2018","journal-title":"Biomark. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108893_b0280","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1002\/jcb.27586","article-title":"Clinical significance of serum DRAM1 mRNA, ARSA mRNA, hsa-miR-2053 and lncRNA-RP1-86D1.3 axis expression in malignant pleural mesothelioma","volume":"120","author":"Matboli","year":"2019","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108893_b0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030221","article-title":"Identification of miRNA-103 in the Cellular Fraction of Human Peripheral Blood as a potential Biomarker for Malignant Mesothelioma - a pilot Study","volume":"7","author":"Weber","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108893_b0290","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1038\/s41598-023-33116-z","article-title":"Epigenetic investigation into circulating microRNA 197-3p in sera from patients affected by malignant pleural mesothelioma and workers ex-exposed to asbestos","volume":"13","author":"Di Mauro","year":"2023","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108893_b0295","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/JTO.0b013e3182572e83","article-title":"Increased Circulating miR-625-3p a potential Biomarker for patients with Malignant Pleural Mesothelioma","volume":"7","author":"Kirschner","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108893_b0300","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010125","article-title":"Serum Extracellular Vesicle-Derived microRNAs as potential Biomarkers for Pleural Mesothelioma in a European prospective Study","volume":"15","author":"Casalone","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108893_b0305","doi-asserted-by":"crossref","first-page":"124","DOI":"10.21037\/tlcr-24-945","article-title":"Potential utility of miRNAs derived from pleural fluid extracellular vesicles to differentiate between benign and malignant pleural effusions","volume":"14","author":"Chee","year":"2025","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108893_b0310","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-020-00194-4","article-title":"Circulating long non-coding RNA GAS5 (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies","volume":"8","author":"Weber","year":"2020","journal-title":"Biomarker Res."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108893_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10112470","article-title":"Molecular Fingerprints of Malignant Pleural Mesothelioma: not just a Matter of Genetic Alterations","volume":"10","author":"Lorenzini","year":"2021","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108893_b0110","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.canlet.2016.05.011","article-title":"CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma","volume":"378","author":"Betti","year":"2016","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108893_b0115","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lungcan.2025.108893_b0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1479-5876-10-179","article-title":"BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs","volume":"10","author":"Carbone","year":"2012","journal-title":"J. Transl. Med."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108893_b0125","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2025.108893_b0130","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jtho.2022.03.014","article-title":"Medical and Surgical Care of Patients with Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations","volume":"17","author":"Carbone","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108893_b0135","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jtho.2016.05.020","article-title":"The Genetic Landscape of Malignant Pleural Mesothelioma: results from Massively Parallel Sequencing","volume":"11","author":"Hylebos","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108893_b0150","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.jtho.2021.05.015","article-title":"DNA Methylation as a Diagnostic Biomarker for Malignant Mesothelioma: a Systematic Review and Meta-Analysis","volume":"16","author":"Vandenhoeck","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108893_b0155","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-08-2586","article-title":"Epigenetic Profiles Distinguish Pleural Mesothelioma from Normal Pleura and Predict Lung Asbestos Burden and Clinical Outcome","volume":"69","author":"Christensen","year":"2009","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108893_b0160","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.lungcan.2004.08.003","article-title":"Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung","volume":"47","author":"Tsou","year":"2005","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108893_b0165","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/npp.2012.112","article-title":"DNA methylation and its basic function","volume":"38","author":"Moore","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.lungcan.2025.108893_b0170","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/jcmm.12094","article-title":"Dynamic and differential regulation in the microRNA expression in the developing and mature cataractous rat lens","volume":"17","author":"Kubo","year":"2013","journal-title":"J. Cell Mol. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108893_b0190","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.coph.2011.04.001","article-title":"Immunohistochemical analysis of FKBP51 in human cancers","volume":"11","author":"Staibano","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"issue":"21","key":"10.1016\/j.lungcan.2025.108893_b0195","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1007\/s00018-018-2895-8","article-title":"ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia","volume":"75","author":"Zhou","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108893_b0210","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108893_b0215","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.molonc.2012.09.006","article-title":"MicroRNA and cancer","volume":"6","author":"Jansson","year":"2012","journal-title":"Mol. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108893_b0220","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1152\/physrev.00006.2010","article-title":"MicroRNAs in development and disease","volume":"91","author":"Sayed","year":"2011","journal-title":"Physiol. Rev."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108893_b0315","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1158\/1055-9965.EPI-10-0346","article-title":"Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma","volume":"19","author":"Creaney","year":"2010","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108893_b0320","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/1055-9965.EPI-08-0422","article-title":"Serum Levels of Soluble Mesothelin-Related Peptides in Malignant and Nonmalignant Asbestos-Related Pleural Disease: Relation with past Asbestos Exposure","volume":"18","author":"Portal","year":"2009","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108893_b0325","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00408-016-9868-1","article-title":"Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure","volume":"194","author":"Demir","year":"2016","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108893_b0330","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s12885-017-3375-5","article-title":"Calretinin as a blood-based biomarker for mesothelioma","volume":"17","author":"Johnen","year":"2017","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108893_b0335","doi-asserted-by":"crossref","first-page":"395","DOI":"10.13075\/ijomeh.1896.00637","article-title":"Validity of mesothelin in occupational medicine practice","volume":"29","author":"Smolkova","year":"2016","journal-title":"Int. J. Occup. Med. Environ. Health"},{"issue":"10","key":"10.1016\/j.lungcan.2025.108893_b0340","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1164\/rccm.200511-1789OC","article-title":"Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma","volume":"173","author":"Scherpereel","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108893_b0345","doi-asserted-by":"crossref","first-page":"883","DOI":"10.7150\/ijms.23939","article-title":"Biomarkers for predicting Malignant Pleural Mesothelioma in a Mexican Population","volume":"15","author":"Aguilar-Madrid","year":"2018","journal-title":"Int. J. Med. Sci."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108893_b0350","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1373\/clinchem.2006.079327","article-title":"MESOMARK: a potential test for malignant pleural mesothelioma","volume":"53","author":"Beyer","year":"2007","journal-title":"Clin. Chem."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108893_b0355","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1378\/chest.07-0013","article-title":"Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma","volume":"132","author":"Creaney","year":"2007","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108893_b0360","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1164\/rccm.200907-1020OC","article-title":"Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma","volume":"181","author":"Hollevoet","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108893_b0365","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000355687","article-title":"Is Soluble Mesothelin-Related Protein an Upfront Predictive Marker of Pleural Mesothelioma? a prospective Study on Italian Workers Exposed to Asbestos","volume":"86","author":"Filiberti","year":"2014","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108893_b0370","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00204-010-0580-2","article-title":"Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos","volume":"85","author":"Gube","year":"2011","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.lungcan.2025.108893_b0375","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1725354","article-title":"Plasma Fibulin-3 as a potential Biomarker for patients with Asbestos-Related Diseases in the Han Population","volume":"2017","author":"Jiang","year":"2017","journal-title":"Dis. Markers"},{"issue":"10","key":"10.1016\/j.lungcan.2025.108893_b0380","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jtho.2021.05.018","article-title":"Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma from Asbestos-Exposed Controls and patients with Other Pleural Diseases","volume":"16","author":"Tsim","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"15","key":"10.1016\/j.lungcan.2025.108893_b0385","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108893_b0390","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2478\/raon-2025-0024","article-title":"Fibulin-3 in plasma and pleural effusion as a biomarker of mesothelioma","volume":"59","author":"Adamic","year":"2025","journal-title":"Radiol. Oncol."},{"issue":"15","key":"10.1016\/j.lungcan.2025.108893_b0395","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMoa051185","article-title":"Asbestos exposure, pleural mesothelioma, and serum osteopontin levels","volume":"353","author":"Pass","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108893_b0405","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/172460081002500307","article-title":"Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma","volume":"25","author":"Cristaudo","year":"2010","journal-title":"Int. J. Biol. Markers"},{"issue":"9","key":"10.1016\/j.lungcan.2025.108893_b0400","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1097\/JTO.0b013e31821e1c08","article-title":"Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma","volume":"6","author":"Cristaudo","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108893_b0410","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00408-013-9526-9","article-title":"Serum Biomarkers in patients with Mesothelioma and Pleural Plaques and healthy Subjects Exposed to naturally Occurring Asbestos","volume":"192","author":"Bayram","year":"2014","journal-title":"Lung"},{"key":"10.1016\/j.lungcan.2025.108893_b0420","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/5756102","article-title":"Serum HMGB1 as a potential Biomarker for patients with Asbestos-Related Diseases","volume":"2017","author":"Ying","year":"2017","journal-title":"Dis. Markers"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108893_b0425","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1089\/ars.2011.3978","article-title":"Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma?","volume":"15","author":"Maeda","year":"2011","journal-title":"Antioxid. Redox Signal."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108893_b0430","doi-asserted-by":"crossref","first-page":"374","DOI":"10.5606\/tgkdc.dergisi.2019.17557","article-title":"Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos","volume":"27","author":"Dongel","year":"2019","journal-title":"Turk Gogus Kalp Damar Cerrahisi Derg"},{"key":"10.1016\/j.lungcan.2025.108893_b0415","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-32315-3","article-title":"Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers","volume":"8","author":"Johnen","year":"2018","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108893_b0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046091","article-title":"Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed individuals with a Noninvasive Proteomics-based Surveillance Tool","volume":"7","author":"Ostroff","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2025.108893_b0440","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3510984","article-title":"A Novel Panel of Serum Biomarkers for MPM Diagnosis","volume":"2017","author":"Bonotti","year":"2017","journal-title":"Dis. Markers"},{"issue":"10","key":"10.1016\/j.lungcan.2025.108893_b0445","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1158\/1055-9965.EPI-20-0543","article-title":"Verification of a Blood-based Targeted Proteomics Signature for Malignant Pleural Mesothelioma","volume":"29","author":"Cerciello","year":"2020","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.lungcan.2025.108893_b0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116662","article-title":"DHEA-S, Androstenedione, 17-beta-estradiol signature as novel biomarkers for early prediction of risk of malignant pleural mesothelioma linked to asbestos-exposure: a preliminary investigation","volume":"175","author":"Nuvoli","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108893_b0455","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1158\/1055-9965.EPI-13-0737","article-title":"Strengths, Weaknesses, and Opportunities of Diagnostic Breathomics in Pleural Mesothelioma-a Hypothesis","volume":"23","author":"Lamote","year":"2014","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"7\u20138","key":"10.1016\/j.lungcan.2025.108893_b0460","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1007\/s00216-010-4238-y","article-title":"Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure","volume":"398","author":"de Gennaro","year":"2010","journal-title":"Anal. Bioanal. Chem."},{"issue":"53","key":"10.1016\/j.lungcan.2025.108893_b0465","doi-asserted-by":"crossref","first-page":"91593","DOI":"10.18632\/oncotarget.21335","article-title":"Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma: a cross-sectional case-control study","volume":"8","author":"Lamote","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108893_b0470","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051262","article-title":"Breath Analysis for Early Detection of Malignant Pleural Mesothelioma: Volatile Organic Compounds (VOCs) Determination and possible Biochemical Pathways","volume":"12","author":"Di Gilio","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108893_b0515","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.lungcan.2011.08.009","article-title":"An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls","volume":"75","author":"Dragonieri","year":"2012","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108893_b0520","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1183\/09031936.00040911","article-title":"A breath test for malignant mesothelioma using an electronic nose","volume":"40","author":"Chapman","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108893_b0525","doi-asserted-by":"crossref","DOI":"10.1088\/1752-7155\/10\/4\/046001","article-title":"Detection of malignant pleural mesothelioma in exhaled breath by multicapillary column\/ion mobility spectrometry (MCC\/IMS)","volume":"10","author":"Lamote","year":"2016","journal-title":"J. Breath Res."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108893_b0530","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00919-2017","article-title":"Exhaled breath to screen for malignant pleural mesothelioma: a validation study","volume":"50","author":"Lamote","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"13","key":"10.1016\/j.lungcan.2025.108893_b0535","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14133182","article-title":"External Validation of a Breath-based Prediction Model for Malignant Pleural Mesothelioma","volume":"14","author":"Janssens","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108893_b0540","doi-asserted-by":"crossref","DOI":"10.1088\/1752-7163\/acf7e3","article-title":"Determining the clinical utility of a breath test for screening an asbestos-exposed population for pleural mesothelioma: baseline results","volume":"17","author":"Zwijsen","year":"2023","journal-title":"J. Breath Res."},{"key":"10.1016\/j.lungcan.2025.108893_b0475","doi-asserted-by":"crossref","unstructured":"Chambers, D.M., et al., Impact of cigarette smoking on volatile organic compound (VOC) blood levels in the U.S. population: NHANES 2003-2004. Environ Int, 2011. 37(8): p. 1321-8.","DOI":"10.1016\/j.envint.2011.05.016"},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2025.108893_b0480","first-page":"64","article-title":"Breath analysis in non small cell lung cancer patients after surgical tumour resection","volume":"79","author":"Poli","year":"2008","journal-title":"Acta Biomed"},{"key":"10.1016\/j.lungcan.2025.108893_b0485","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.isci.2018.12.008","article-title":"Profiling Single Cancer Cells with Volatolomics Approach","volume":"11","author":"Serasanambati","year":"2019","journal-title":"iScience"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108893_b0490","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jtho.2016.02.017","article-title":"Exhaled Breath Analysis for monitoring Response to Treatment in Advanced Lung Cancer","volume":"11","author":"Nardi-Agmon","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108893_b0495","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174802","article-title":"Clinical contributions of exhaled volatile organic compounds in the diagnosis of lung cancer","volume":"12","author":"Oguma","year":"2017","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.lungcan.2025.108893_b0500","first-page":"5116","article-title":"Rational lung tissue and animal models for rapid breath tests to determine pneumonia and pathogens","volume":"9","author":"Zhou","year":"2017","journal-title":"Am. J. Transl. Res."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108893_b0505","article-title":"Limonene in exhaled breath is elevated in hepatic encephalopathy","volume":"10","author":"O'Hara","year":"2016","journal-title":"J. Breath Res."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108893_b0510","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1515\/CCLM.2009.133","article-title":"Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry","volume":"47","author":"Ligor","year":"2009","journal-title":"Clin. Chem. Lab. Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225007858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225007858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T08:12:44Z","timestamp":1768983164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225007858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":108,"alternative-id":["S0169500225007858"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108893","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-omic screening for pleural mesothelioma in Asbestos-Exposed Populations: A literature review and Recommendations","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108893"}}